Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.44 |
| ▸ | MMP9 | P14780 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.44 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 5/20 | 0.40 |
| ▸ | MMP13 | P45452 | 4/20 | 0.40 |
| ▸ | MMP3 | P08254 | 4/20 | 0.40 |
| ▸ | MMP7 | P09237 | 2/20 | 0.40 |
| ▸ | BMP1 | P13497 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6199952 | 0.92 | PSEN1 (0.43) | MMP2MMP9OPRK1LIMK2OPRM1 | |
| SCHEMBL6199527 | 0.89 | MMP2 (0.48) | MMP2MMP9ALDH1A1POLBMMP1 | |
| SCHEMBL1601963 | 0.89 | MMP2 (0.48) | MMP2MMP9LIMK2ALDH1A1POLB | |
| SCHEMBL5771495 | 0.87 | OPRK1 (0.39) | MMP2MMP9OPRK1LIMK2OPRM1 | |
| SCHEMBL1602742 | 0.86 | MMP2 (0.47) | MMP2MMP9ALDH1A1POLBMMP1 | |
| SCHEMBL1601507 | 0.85 | MMP2 (0.47) | MMP2MMP9ALDH1A1POLBMMP1 | |
| SCHEMBL1602818 | 0.85 | MMP2 (0.44) | MMP2MMP9ALDH1A1POLBMMP1 | |
| SCHEMBL1602159 | 0.82 | MMP2 (0.42) | MMP2MMP9ALDH1A1POLBMMP1 | |
| SCHEMBL1602322 | 0.82 | ABCB1 (0.51) | — | |
| SCHEMBL1600931 | 0.82 | ABCB1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919523-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20090042973-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042973-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | MMP2 279/4885MMP9 479/4885OPRK1 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.